Oligonucleotide Sequences Targeting Transcription FactorTSC22D4 for the Treatment of Insulin Resistance
AssigneeDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsStephan HERZIG, Mauricio BARRIEL DIAZ, Tobias SCHAFMEIER
Life of this patent
Estimating the term…
Abstract
The present invention relates to oligonucleotide inhibitors of the TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.
Claims15
An inhibitor of the-expression and/or biological activity of TSC22D4 wherein said inhibitor is selected from an oligonucleotide that is an interfering ribonucleic acid, PNA (protein nucleic acid) or LNA (locked nucleic acid), and wherein said oligonucleotide comprises at least one sequence selected from:
- 5′-GGACGUGUGUGGAUGUUUAdTdT-3′ (SEQ ID NO:
- 1);
- 5′-GGAUGUUUACGAGAGAGAUdTdT-3′ (SEQ ID NO:
- 2);
- 5′-AGUCCCACCUCAUGUUUGCdTdT-3′ (SEQ ID NO:
- 3);
- antisense sequences thereof, and functional variants thereof.
Dependencies are inferred from the claim text.